Cell-based assay identifies new anti cancer drugs
2021
Max Planck Institute of Molecular Physiology, Dortmund, Germany
Cancer immune escape is a common problem in cancer therapy. Cells have developed different strategies to evade immune-cell mediated elimination, for example, the modulation of immune checkpoints. The immunoregulatory enzyme indoleamine‐2,3‐dioxygenase (IDO1) is a protein often responsible for this effect and IDO1-inhibitors are hence a potential target for anti-cancer drug discovery. Yet the screening for IDO1 inhibitors was not that successful. This newly developed assay used human cancer cell lines and the chemical reaction the protein catalyzes to form kynurenine, which is measured. Thus, new IDO1 inhibitors and regulators with a potential clinical application could be identified usingthis high throughput method.
Cell‐based identification of new IDO1 modulator chemotypes
Herbert Waldmann
Added on: 05-03-2021
[1] www.onlinelibrary.wiley.com/doi/10.1002/anie.202016004[2] https://www.bionity.com/en/news/1170410/stimulating-the-immune-system-to-fight-cancer.html
